Arthritis Differential DIagnostic validaTION

Project Information

ADDITION

Grant agreement ID: 662712

DOI 10.3030/662712

Project closed

EC signature date 4 March 2015

Start date 1 April 2015

End date 30 September 2015

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

DNALYTICS
Belgium

Objective

Arthritis, a group of diseases involving inflammation of joints with huge health and socio-economic impacts. Early Arthritis
(EA) describes newly diagnosed arthritis (incidence 2/1000). An improved arthritis management requires to enhance the EA
differential diagnostic efficacy and the adequacy of the therapeutic strategies. The earlier arthritis is addressed, the more
likely its progression will be limited. A mistake in differential diagnostic leads to inappropriate treatments, resulting in useless
expenses and serious side effects, unjustified. Current diagnostic techniques are unsatisfactory and the most used first line
treatment, Methotrexate (MTX), is ineffective in about 40% of the patients. RheumaKit is a solution for clinicians for the early
differential diagnostic of patients suffering from undifferentiated arthritis (UA, a subclass of EA). RheumaKit is based on a
trancriptomic signature of about 100 genes complemented by 3 clinical factors. It provides a 90% accuracy for the
Rheumatoid Arthritis (RA) vs non-RA distinction, far above the ACR/EULAR2010 criterion on the same patients. It also
provides probabilities for Osteoarthritis and Seronegative Spondylarthropaties. The solution consists of a synovial biopsy
collection and transportation kit (CE-marked May 2014), a central lab PCR procedure, and a web application computing the
effective diagnostic on a cloud-computing infrastructure. Functional, technical, logistics aspects of RheumaKit have been
validated. ADDITION aims at clinically validate on a larger patient cohort the existing RheumaKit signature for the differential
diagnostic of most EA patients and validate the use of the existing RheumaKit signature as a tool to predict MTX response.
ADDITION phase 2 will involve a prospective study on 500 to 1000 EA patients. The main phase 1 objectives are a feasibility
study of the clinical and market aspects of ADDITION. The expected annual turnover is above 140M€-280M€ in EU within a
few years.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• medical and health sciences › clinical medicine › rheumatology
• engineering and technology › medical engineering › medical laboratory technology › diagnostic technologies
• natural sciences › computer and information sciences › software › software applications

You need to log in or register to use this function

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Topic(s)

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Call for proposal

H2020-SMEInst-2014-2015

See other projects for this call

Sub call

H2020-SMEINST-1-2014

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

DNALYTICS

• Net EU contribution: € 50 000,00
• Address: CHEMIN DU CYCLOTRON 6 ; 1348 OTTIGNIES LOUVAIN LA NEUVE ; Belgium
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Région wallonne › Prov. Brabant Wallon › Arr. Nivelles
• Region: Région wallonne › Prov. Brabant Wallon › Arr. Nivelles
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 71 429,00